Aktienanalyse zu Maze Therapeutics Inc (MAZE)MAZEMaze Therapeutics Inc

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target. It operates in the Healthcare sector.

Maze Therapeutics is currently priced at $27.44, which is significantly below the analyst price targets ranging from $56 to $110, indicating potential upside. However, the RSI is at 32.918, suggesting the stock is oversold, but the recent 5-day change of -6.76% raises concerns about short-term volatility. The main risk is the company's ongoing negative earnings, with a net income loss of $44.7 million reported in Q2 2026, which could affect investor sentiment.